GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT05649137

CompletedPhase 3Results posted

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity and Type 2 Diabetes

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

512

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥30•HbA1c 7-10%

Primary endpoints

•Body weight, % change•≥5% weight-loss responders

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05649137

Org study IDNN9536-7545

Secondary ID2022-002235-60

Secondary IDU1111-1279-0359World Health Organization (WHO)

Timeline

Milestones

Study first posted2022-12-13actual

Study start2023-01-04actual

Primary completion2024-10-28actual

Study completion2024-12-13actual

Last update posted2026-04-27actual

Results first posted2026-04-27actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or female.

•Age above or equal to 18 years at the time of signing informed consent.

•BMI greater than or equal to 30.0 kilograms per square meter (kg/m^2).

•Diagnosed with type 2 diabetes (T2D) greater than or equal to 180 days prior to the day of screening.

•History of at least one self-reported unsuccessful dietary effort to lose body weight.

•HbA1c 7.0-10.0 percent (53-86 millimoles per mole [mmol/mol]) (both inclusive) as measured by central laboratory at screening.

Exclusion criteria

•A self-reported change in body weight greater than 5 kilograms (kg) (11 pounds [lbs]) within 90 days before screening irrespective of medical records.

•Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.

•Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than 30 milliliters per minute per 1.73 square meter (30 mL/min/1.73 m^2) (less than 45 mL/min/1.73 m^2 in participants treated with Sodium-glucose Cotransporter-2 [SGLT2i]) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by Kidney Disease: Improving Global Outcomes (KDIGO) 2012 by the central laboratory at screening.

•Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

Endpoints (72)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Weight & body composition

Glycemic / diabetes

Safety / tolerability / PK

Weight & body composition

16 endpoints

Primary/registry result

Relative Change in Body Weight

Time frame:Baseline (week 0), End of treatment (week 72)

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (mean), Percentage (%) change in body weight	95% CI
Semaglutide 7.2 mg	-13.5	—
Semaglutide 2.4 mg	-10.7	—
Placebo	-4.0	—

Treatment difference-9.3395% CI-10.95 – -7.71p<0.0001ANCOVA

Primary/registry result

Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)

Time frame:At week 72

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 7.2 mg	251	—
	40	—
Semaglutide 2.4 mg	73	—
	24	—
Placebo	33	—
	62	—

Odds Ratio (OR)10.0395% CI5.96 – 16.87p<0.0001Binary regression model

Primary/protocol endpoint

Relative Change in Body Weight

Time frame:Baseline (week 0), End of treatment (week 72)

Body weight, % change

percent change from baseline, improvement

Primary/protocol endpoint

Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)

Time frame:At week 72

≥5% weight-loss responders

threshold achievement, improvement

Secondary/registry result

Number of Participants Who Achieve Body Weight Reduction >= 10% (Yes/no)

Time frame:At week 72

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 7.2 mg	183	—
	108	—
Semaglutide 2.4 mg	50	—
	47	—
Placebo	11	—
	84	—

Secondary/registry result

Number of Participants Who Achieve Body Weight Reduction >= 15% (Yes/no)

Time frame:At week 72

≥15% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 7.2 mg	120	—
	171	—
Semaglutide 2.4 mg	28	—
	69	—
Placebo	7	—
	88	—

Secondary/registry result

Number of Participants Who Achieve Body Weight Reduction >= 20% (Yes/no)

Time frame:At week 72

≥20% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 7.2 mg	62	—
	229	—
Semaglutide 2.4 mg	14	—
	83	—
Placebo	2	—
	93	—

Secondary/registry result

Change in Waist Circumference

Time frame:Baseline (week 0), End of treatment (week 72)

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (mean), Centimeters (cm)	95% CI
Semaglutide 7.2 mg	-12.6	—
Semaglutide 2.4 mg	-10.6	—
Placebo	-6.5	—

Secondary/registry result

Change in Body Weight

Time frame:Baseline (week 0), End of treatment (week 72)

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (mean), Kilograms (kg)	95% CI
Semaglutide 7.2 mg	-14.9	—
Semaglutide 2.4 mg	-11.4	—
Placebo	-4.6	—

Secondary/registry result

Change in Body Mass Index (BMI)

Time frame:Baseline (week 0), End of treatment (week 72)

BMI, change

change from baseline, improvement

Posted result

Group	Value (mean), kilograms per meter square (kg/m^2)	95% CI
Semaglutide 7.2 mg	-5.3	—
Semaglutide 2.4 mg	-4.1	—
Placebo	-1.6	—

Secondary/protocol endpoint

Number of Participants Who Achieve Body Weight Reduction >= 10% (Yes/no)

Time frame:At week 72

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Number of Participants Who Achieve Body Weight Reduction >= 15% (Yes/no)

Time frame:At week 72

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Number of Participants Who Achieve Body Weight Reduction >= 20% (Yes/no)

Time frame:At week 72

≥20% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change in Waist Circumference

Time frame:Baseline (week 0), End of treatment (week 72)

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Weight

Time frame:Baseline (week 0), End of treatment (week 72)

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Mass Index (BMI)

Time frame:Baseline (week 0), End of treatment (week 72)

BMI, change

change from baseline, improvement

Glycemic / diabetes

12 endpoints

Secondary/registry result

Change in Glycated Haemoglobin (HbA1c)

Time frame:Baseline (week 0), End of treatment (week 72)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), Percentage of HbA1c	95% CI
Semaglutide 7.2 mg	-1.8	—
Semaglutide 2.4 mg	-1.7	—
Placebo	-0.3	—

Secondary/registry result

Change in Fasting Plasma Glucose

Time frame:Baseline (week 0), End of treatment (week 72)

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (mean), mg/dL	95% CI
Semaglutide 7.2 mg	-59.6	—
Semaglutide 2.4 mg	-58.4	—
Placebo	-20.2	—

Secondary/registry result

Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of fasting serum insulin	95% CI
Semaglutide 7.2 mg	0.77	—
Semaglutide 2.4 mg	0.90	—
Placebo	0.87	—

Secondary/registry result/low confidence

Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of fasting serum insulin	95% CI
Semaglutide 7.2 mg	0.77	—
Semaglutide 2.4 mg	0.90	—
Placebo	0.87	—

Secondary/registry result

Number of Participants With HbA1c Less Than 7.0 % (53 Millimoles Per Mole [mmol/Mol])

Time frame:At week 72

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 7.2 mg	235	—
Semaglutide 2.4 mg	75	—
Placebo	27	—

Secondary/registry result

Number of Participants With HbA1c Less Than or Equal to 6.5% (48 mmol/Mol)

Time frame:At week 72

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 7.2 mg	209	—
Semaglutide 2.4 mg	64	—
Placebo	15	—

Secondary/protocol endpoint

Change in Glycated Haemoglobin (HbA1c)

Time frame:Baseline (week 0), End of treatment (week 72)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in Fasting Plasma Glucose

Time frame:Baseline (week 0), End of treatment (week 72)

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

ratio, improvement

Secondary/protocol endpoint

Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

ratio, improvement

Secondary/protocol endpoint

Number of Participants With HbA1c Less Than 7.0 % (53 Millimoles Per Mole [mmol/Mol])

Time frame:At week 72

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Number of Participants With HbA1c Less Than or Equal to 6.5% (48 mmol/Mol)

Time frame:At week 72

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

Cardiometabolic biomarkers

32 endpoints

Secondary/registry result

Change in Systolic Blood Pressure

Time frame:Baseline (week 0), End of treatment (week 72)

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Posted result

Group	Value (mean), Millimeters of mercury (mmHg)	95% CI
Semaglutide 7.2 mg	-8	—
Semaglutide 2.4 mg	-7	—
Placebo	-3	—

Secondary/registry result

Change in Diastolic Blood Pressure

Time frame:Baseline (week 0), End of treatment (week 72)

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Posted result

Group	Value (mean), mmHg	95% CI
Semaglutide 7.2 mg	-3	—
Semaglutide 2.4 mg	-3	—
Placebo	-3	—

Secondary/registry result

Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Posted result

Group	Value (geometric_mean), Ratio of total cholesterol	95% CI
Semaglutide 7.2 mg	0.96	—
Semaglutide 2.4 mg	0.96	—
Placebo	0.97	—

Secondary/registry result

Change in Total Cholesterol (Milligrams Per Deciliter [mg/dL]) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Posted result

Group	Value (geometric_mean), Ratio of total cholesterol	95% CI
Semaglutide 7.2 mg	0.96	—
Semaglutide 2.4 mg	0.96	—
Placebo	0.97	—

Secondary/registry result

Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

HDL-C, change

ratio, improvement

LOINC 2085-9

Posted result

Group	Value (geometric_mean), Ratio of HDL cholesterol	95% CI
Semaglutide 7.2 mg	1.10	—
Semaglutide 2.4 mg	1.06	—
Placebo	1.07	—

Secondary/registry result

Change in HDL Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

HDL-C, change

ratio, improvement

LOINC 2085-9

Posted result

Group	Value (geometric_mean), Ratio of HDL cholesterol	95% CI
Semaglutide 7.2 mg	1.10	—
Semaglutide 2.4 mg	1.06	—
Placebo	1.07	—

Secondary/registry result

Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

LDL-C, change

ratio, improvement

LOINC 13457-7

Posted result

Group	Value (geometric_mean), Ratio of LDL cholesterol	95% CI
Semaglutide 7.2 mg	0.99	—
Semaglutide 2.4 mg	0.95	—
Placebo	0.97	—

Secondary/registry result

Change in LDL Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

LDL-C, change

ratio, improvement

LOINC 13457-7

Posted result

Group	Value (geometric_mean), Ratio of LDL cholesterol	95% CI
Semaglutide 7.2 mg	0.99	—
Semaglutide 2.4 mg	0.95	—
Placebo	0.97	—

Secondary/registry result

Change in Very-low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

VLDL, change

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of VLDL cholesterol	95% CI
Semaglutide 7.2 mg	0.72	—
Semaglutide 2.4 mg	0.81	—
Placebo	0.90	—

Secondary/registry result

Change in VLDL Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

VLDL, change

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of VLDL cholesterol	95% CI
Semaglutide 7.2 mg	0.72	—
Semaglutide 2.4 mg	0.81	—
Placebo	0.90	—

Secondary/registry result

Change in Triglycerides (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Triglycerides, change

ratio, improvement

LOINC 2571-8

Posted result

Group	Value (geometric_mean), Ratio of triglycerides	95% CI
Semaglutide 7.2 mg	0.71	—
Semaglutide 2.4 mg	0.80	—
Placebo	0.87	—

Secondary/registry result

Change in Triglycerides (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Triglycerides, change

ratio, improvement

LOINC 2571-8

Posted result

Group	Value (geometric_mean), Ratio of triglycerides	95% CI
Semaglutide 7.2 mg	0.71	—
Semaglutide 2.4 mg	0.80	—
Placebo	0.87	—

Secondary/registry result

Change in Free Fatty Acids (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Free fatty acids, change

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of free fatty acids	95% CI
Semaglutide 7.2 mg	0.74	—
Semaglutide 2.4 mg	0.81	—
Placebo	0.98	—

Secondary/registry result

Change in Free Fatty Acids (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Free fatty acids, change

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of free fatty acids	95% CI
Semaglutide 7.2 mg	0.74	—
Semaglutide 2.4 mg	0.81	—
Placebo	0.98	—

Secondary/registry result

Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

hs-CRP, change

ratio, improvement

LOINC 30522-7

Posted result

Group	Value (geometric_mean), Ratio of hsCRP	95% CI
Semaglutide 7.2 mg	0.47	—
Semaglutide 2.4 mg	0.48	—
Placebo	0.82	—

Secondary/registry result

Change in Pulse

Time frame:Baseline (week 0), End of treatment (week 72)

Heart rate, change

change from baseline, improvement

Posted result

Group	Value (mean), Beats per minute (bpm)	95% CI
Semaglutide 7.2 mg	1	—
Semaglutide 2.4 mg	2	—
Placebo	-4	—

Secondary/protocol endpoint

Change in Systolic Blood Pressure

Time frame:Baseline (week 0), End of treatment (week 72)

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in Diastolic Blood Pressure

Time frame:Baseline (week 0), End of treatment (week 72)

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in Total Cholesterol (Milligrams Per Deciliter [mg/dL]) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

HDL-C, change

ratio, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in HDL Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

HDL-C, change

ratio, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

LDL-C, change

ratio, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in LDL Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

LDL-C, change

ratio, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in Very-low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

VLDL, change

ratio, improvement

Secondary/protocol endpoint

Change in VLDL Cholesterol (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

VLDL, change

ratio, improvement

Secondary/protocol endpoint

Change in Triglycerides (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Triglycerides, change

ratio, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in Triglycerides (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Triglycerides, change

ratio, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in Free Fatty Acids (mmol/L) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Free fatty acids, change

ratio, improvement

Secondary/protocol endpoint

Change in Free Fatty Acids (mg/dL) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

Free fatty acids, change

ratio, improvement

Secondary/protocol endpoint

Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline

Time frame:Baseline (week 0), End of treatment (week 72)

hs-CRP, change

ratio, improvement

LOINC 30522-7

Secondary/protocol endpoint

Change in Pulse

Time frame:Baseline (week 0), End of treatment (week 72)

Heart rate, change

change from baseline, improvement

Safety / tolerability / PK

12 endpoints

Secondary/registry result

Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)

Time frame:At week 81

Treatment-emergent AEs (any)

event count, event

Posted result

Group	Value (number), Events	95% CI
Semaglutide 7.2 mg	1581	—
Placebo	253	—

Secondary/registry result

Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)

Time frame:At week 81

Serious AEs (any)

event count, event

Posted result

Group	Value (number), Events	95% CI
Semaglutide 7.2 mg	39	—
Placebo	21	—

Secondary/registry result

Semaglutide 7.2 mg Versus Placebo: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

Time frame:At week 81

Documented hypoglycemia

event count, event

componentsSevere hypoglycemia, Documented hypoglycemia

Posted result

Group	Value (number), Episodes	95% CI
Semaglutide 7.2 mg	0	—
Placebo	1	—

Secondary/registry result

Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs

Time frame:At week 81

Treatment-emergent AEs (any)

event count, event

Posted result

Group	Value (number), Events	95% CI
Semaglutide 7.2 mg	1581	—
Semaglutide 2.4 mg	508	—

Secondary/registry result

Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs

Time frame:At week 81

Serious AEs (any)

event count, event

Posted result

Group	Value (number), Events	95% CI
Semaglutide 7.2 mg	39	—
Semaglutide 2.4 mg	35	—

Secondary/registry result

Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

Time frame:At week 81

Documented hypoglycemia

event count, event

componentsSevere hypoglycemia, Documented hypoglycemia

Posted result

Group	Value (number), Episodes	95% CI
Semaglutide 7.2 mg	0	—
Semaglutide 2.4 mg	0	—

Secondary/protocol endpoint

Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)

Time frame:At week 81

Treatment-emergent AEs (any)

event count, event

Secondary/protocol endpoint

Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)

Time frame:At week 81

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Semaglutide 7.2 mg Versus Placebo: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

Time frame:At week 81

Documented hypoglycemia

event count, event

componentsSevere hypoglycemia, Documented hypoglycemia

Secondary/protocol endpoint

Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs

Time frame:At week 81

Treatment-emergent AEs (any)

event count, event

Secondary/protocol endpoint

Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs

Time frame:At week 81

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

Time frame:At week 81

Documented hypoglycemia

event count, event

componentsSevere hypoglycemia, Documented hypoglycemia

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.
The lancet. Diabetes & endocrinology2025 Nov (month)PMID40961953doi:10.1016/S2213-8587(25)00225-6via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.